U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® for Adults With Moderately to Severely Active Crohn's Disease

Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In the pivotal Phase 3 AFFIRM study, subcutaneous (SC) SKYRIZI® achieved superior clinical remissioni a...
This is a short summary. The full story is published by Investing News Network (inn).
Read full story at Investing News Network (inn)

